[go: up one dir, main page]

PE20080315A1 - DERIVADOS DE PIRAZOLO-[3,4-d]-PIRIMIDINAS COMO INHIBIDORES DE CINASA PI-3 - Google Patents

DERIVADOS DE PIRAZOLO-[3,4-d]-PIRIMIDINAS COMO INHIBIDORES DE CINASA PI-3

Info

Publication number
PE20080315A1
PE20080315A1 PE2007000620A PE2007000620A PE20080315A1 PE 20080315 A1 PE20080315 A1 PE 20080315A1 PE 2007000620 A PE2007000620 A PE 2007000620A PE 2007000620 A PE2007000620 A PE 2007000620A PE 20080315 A1 PE20080315 A1 PE 20080315A1
Authority
PE
Peru
Prior art keywords
alkyl
kinase
pyrimidin
amine
phenyl
Prior art date
Application number
PE2007000620A
Other languages
English (en)
Inventor
Ian Bruce
Graham Charles Bloomfield
Brian Cox
Catherine Howsham
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36687588&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20080315(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20080315A1 publication Critical patent/PE20080315A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

REFERIDA A UN COMPUESTO PIRAZOLO-[3,4-d]-PIRIMIDINA DE FORMULA (I), DONDE R1 ES ALQUILO C1-C3 OPCIONALMENTE SUSTITUIDO CON UNO A SIETE ATOMOS DE FLUOR; R2 ES UN GRUPO HETEROARILO DE 5 A 6 MIEMBROS O UN FENILO, OPCIONALMENTE SUSTITUIDOS POR UN GRUPO CIANO, ALQUILO C1-C8, UN GRUPO NITRO, ENTRE OTROS; R3 ES H, AMINO O ALQUIL C1-C3-AMINO; Y ES H, ALQUILO C1-C8, ALCOXILO C1-C8, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 3-(3-FLUORO-4-METOXI-FENIL)-1-METIL-1H-PIRAZOLO-[3,4-d]-PIRIMIDIN-6-IL-AMINA, 3-BENZO[1,3]DIOXOL-5-IL-1-METIL-1H-PIRAZOLO-[3,4-d]-PIRIMIDIN-6-IL-AMINA, 3-(3-FLUORO-FENIL)-1-METIL-1H-PIRAZOLO-[3,4-d]-PIRIMIDIN-6-IL-AMINA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA CINASA DE FOSFATIDIL-INOSITOL-3 (CINASA PI-3) Y SON UTILES EN EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS U OBSTRUCTIVAS DE LAS VIAS RESPIRATORIAS
PE2007000620A 2006-05-23 2007-05-21 DERIVADOS DE PIRAZOLO-[3,4-d]-PIRIMIDINAS COMO INHIBIDORES DE CINASA PI-3 PE20080315A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0610242.0A GB0610242D0 (en) 2006-05-23 2006-05-23 Organic compounds

Publications (1)

Publication Number Publication Date
PE20080315A1 true PE20080315A1 (es) 2008-06-11

Family

ID=36687588

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000620A PE20080315A1 (es) 2006-05-23 2007-05-21 DERIVADOS DE PIRAZOLO-[3,4-d]-PIRIMIDINAS COMO INHIBIDORES DE CINASA PI-3

Country Status (24)

Country Link
US (5) US20090131457A1 (es)
EP (1) EP2026811A1 (es)
JP (1) JP2009537580A (es)
KR (1) KR101106853B1 (es)
CN (1) CN101443013A (es)
AR (2) AR061057A1 (es)
AU (1) AU2007253615B2 (es)
BR (1) BRPI0712022A2 (es)
CA (1) CA2650661A1 (es)
CL (1) CL2007001455A1 (es)
CR (1) CR10419A (es)
EC (1) ECSP088902A (es)
GB (1) GB0610242D0 (es)
GT (1) GT200800256A (es)
IL (1) IL195017A0 (es)
MA (1) MA30433B1 (es)
MX (1) MX2008014835A (es)
NO (1) NO20084997L (es)
PE (1) PE20080315A1 (es)
RU (1) RU2008150619A (es)
TN (1) TNSN08478A1 (es)
TW (1) TW200806665A (es)
WO (1) WO2007134828A1 (es)
ZA (1) ZA200809097B (es)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1831225A2 (en) 2004-11-19 2007-09-12 The Regents of the University of California Anti-inflammatory pyrazolopyrimidines
KR20120051760A (ko) 2006-04-04 2012-05-22 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 키나제 길항물질
JP5485884B2 (ja) * 2007-07-26 2014-05-07 ノバルティス アーゲー 炎症性またはアレルギー性状態の処置に有用なピリミジン誘導体
CA2694136C (en) 2007-08-02 2013-09-17 Amgen Inc. Pi3 kinase modulators and methods of use
GB2467670B (en) 2007-10-04 2012-08-01 Intellikine Inc Chemical entities and therapeutic uses thereof
WO2009085230A1 (en) 2007-12-19 2009-07-09 Amgen Inc. Inhibitors of pi3 kinase
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
JP5869222B2 (ja) 2008-01-04 2016-02-24 インテリカイン， エルエルシー 特定の化学的実体、組成物および方法
WO2009114874A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Benzothiazole kinase inhibitors and methods of use
WO2009114870A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Kinase inhibitors and methods of use
EP2111861A1 (en) * 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
MX315904B (es) 2008-05-30 2013-11-29 Amgen Inc Inhibidores de fosfoinosituro-3 cinasa.
WO2010006072A2 (en) 2008-07-08 2010-01-14 The Regents Of The University Of California Mtor modulators and uses thereof
WO2010006086A2 (en) 2008-07-08 2010-01-14 Intellikine, Inc. Kinase inhibitors and methods of use
US8220787B2 (en) * 2008-09-19 2012-07-17 Panasonic Corporation Part mounting device
EP2346508B1 (en) 2008-09-26 2016-08-24 Intellikine, LLC Heterocyclic kinase inhibitors
AU2009305669A1 (en) 2008-10-16 2010-04-22 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
EP2414361A1 (en) 2009-03-31 2012-02-08 ArQule, Inc. Substituted heterocyclic compounds
JP5789252B2 (ja) 2009-05-07 2015-10-07 インテリカイン， エルエルシー 複素環式化合物およびその使用
EP2488511A1 (en) * 2009-10-02 2012-08-22 Vertex Pharmaceuticals Incorporated Pyrazole inhibitors of phosphatidylinositol 3-kinase
US8980899B2 (en) 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
GB201004311D0 (en) 2010-03-15 2010-04-28 Proximagen Ltd New enzyme inhibitor compounds
WO2011146313A1 (en) * 2010-05-19 2011-11-24 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
EP2571357B1 (en) 2010-05-21 2016-07-06 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
CA2817577A1 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
SG10201600179RA (en) 2011-01-10 2016-02-26 Infinity Pharmaceuticals Inc Processes for preparing isoquinolinones and solid forms of isoquinolinones
US8362023B2 (en) 2011-01-19 2013-01-29 Hoffmann-La Roche Inc. Pyrazolo pyrimidines
CN103491962B (zh) 2011-02-23 2016-10-12 因特利凯有限责任公司 激酶抑制剂的组合及其用途
EP2734520B1 (en) 2011-07-19 2016-09-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX2014000648A (es) 2011-07-19 2014-09-25 Infinity Pharmaceuticals Inc Compuestos heterociclicos y sus usos.
KR20140075693A (ko) 2011-08-29 2014-06-19 인피니티 파마슈티칼스, 인코포레이티드 헤테로사이클릭 화합물 및 그의 용도
MX370814B (es) 2011-09-02 2020-01-08 Univ California Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
EA201490451A1 (ru) 2011-09-14 2014-12-30 Проксимаген Лимитед Новые соединения - ингибиторы ферментов
GB201115853D0 (en) 2011-09-14 2011-10-26 Proximagen Ltd New enzyme inhibitor compounds
ES2650630T3 (es) 2011-10-03 2018-01-19 The University Of North Carolina At Chapel Hill Compuestos de pirrolopirimidina para el tratamiento del cáncer
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
HK1206338A1 (en) 2012-05-22 2016-01-08 北卡罗来纳大学教堂山分校 Pyrimidine compounds for the treatment of cancer
BR112014028881A2 (pt) 2012-05-23 2017-06-27 Hoffmann La Roche populações de células, banco de células, métodos de obtenção de uma população de células, métodos de identificação de um fator, métodos de seleção, métodos de fornecimento de terapia, populações de hepatócitos e método de obtenção de células
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
SG11201502331RA (en) 2012-09-26 2015-04-29 Univ California Modulation of ire1
US9562047B2 (en) 2012-10-17 2017-02-07 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
HUE040126T2 (hu) 2012-11-01 2019-02-28 Infinity Pharmaceuticals Inc Rákok kezelése PI3 kináz izoform modulátorok alkalmazásával
EP2925752A4 (en) 2012-11-27 2016-06-01 Univ North Carolina PYRIMIDINE COMPOUNDS FOR CANCER TREATMENT
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
WO2014153509A1 (en) 2013-03-22 2014-09-25 Millennium Pharmaceuticals, Inc. Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX389256B (es) 2013-10-04 2025-03-20 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos.
WO2015143012A1 (en) 2014-03-19 2015-09-24 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
WO2015157122A1 (en) 2014-04-11 2015-10-15 The University Of North Carolina At Chapel Hill Mertk-specific pyrazolopyrimidine compounds
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CZ308056B6 (cs) * 2015-07-20 2019-11-27 Ustav Experimentalni Botaniky Av Cr V V I 5-Substituované-7-[4-(substituované)benzyl]amino-3-isopropylpyrazolo[4,3-d]pyrimidiny, jejich použití jako antirevmatika, a farmaceutické přípravky
EP4585268A3 (en) 2015-09-14 2025-10-15 Twelve Therapeutics, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
US10709708B2 (en) 2016-03-17 2020-07-14 The University Of North Carolina At Chapel Hill Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor
US10954241B2 (en) 2016-04-15 2021-03-23 Cancer Research Technology Limited Heterocyclic compounds as ret kinase inhibitors
EP4104837A3 (en) 2016-04-15 2023-04-26 Cancer Research Technology Limited Heterocyclic compounds as ret kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
UA125216C2 (uk) 2016-06-24 2022-02-02 Інфініті Фармасьютікалз, Інк. Комбінована терапія
JOP20180009A1 (ar) * 2017-02-06 2019-01-30 Gilead Sciences Inc مركبات مثبط فيروس hiv
GB201705971D0 (en) 2017-04-13 2017-05-31 Cancer Res Tech Ltd Inhibitor compounds
JP2023508978A (ja) * 2019-12-23 2023-03-06 サンフォード バーナム プレビス メディカル ディスカバリー インスティテュート エクトヌクレオチドピロホスファターゼ／ホスホジエステラーゼ１（ｅｎｐｐ１）モジュレーター及びその使用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR205429A1 (es) * 1971-04-27 1976-05-07 Ciba Geigy Ag Procedimiento para la elaboracion de nuevos derivados de 4-amino - 3-(5-nitro- 2 -furil)-1-metil - 1h - pirazol-(3,4-ol)-pirimidina
AR204665A1 (es) * 1974-05-13 1976-02-20 Lilly Co Eli Procedimiento para preparar compuestos de 3-(5-nitroimidazol-2-il)pirazolo(3,4d)pirimidina
US4044130A (en) * 1974-07-03 1977-08-23 Ciba-Geigy Corporation Compositions for the control of microorganisms
JPS5195094A (en) * 1975-01-31 1976-08-20 * ***** ****so*shi***** *o*u****** ********ne***u**** *** *** ****ne*** *************te***ku**
ATE283700T1 (de) * 1999-06-08 2004-12-15 Lorantis Ltd Therapeutische verwendung eines inhibitors des hedgehog signalübertragungsweges
SK3812002A3 (en) * 1999-09-17 2003-09-11 Abbott Gmbh & Co Kg Pyrazolopyrimidines as therapeutic agents
HRP20020838A2 (en) * 2000-04-25 2004-12-31 Icos Corp Inhibitors of human phosphatidyl-inositol 3-kinase delta
AU2002341920A1 (en) * 2001-10-02 2003-04-14 Smithkline Beecham Corporation Chemical compounds
WO2003082341A1 (en) 2002-03-22 2003-10-09 Cellular Genomics, Inc. AN IMPROVED FORMULATION OF CERTAIN PYRAZOLO[3,4-d] PYRIMIDINES AS KINASE MODULATORS
US7429596B2 (en) * 2003-06-20 2008-09-30 The Regents Of The University Of California 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
CA2553724A1 (en) * 2004-02-03 2005-08-18 Abbott Laboratories Aminobenzoxazoles as therapeutic agents
EP1831225A2 (en) * 2004-11-19 2007-09-12 The Regents of the University of California Anti-inflammatory pyrazolopyrimidines
AU2007245129A1 (en) * 2006-03-29 2007-11-08 Foldrx Pharmaceuticals, Inc. Inhibition of alpha-synuclein toxicity

Also Published As

Publication number Publication date
KR20090008392A (ko) 2009-01-21
US20160303132A1 (en) 2016-10-20
MX2008014835A (es) 2008-12-01
GT200800256A (es) 2009-05-28
US20140235632A1 (en) 2014-08-21
MA30433B1 (fr) 2009-05-04
CA2650661A1 (en) 2007-11-29
US8901134B2 (en) 2014-12-02
CN101443013A (zh) 2009-05-27
KR101106853B1 (ko) 2012-01-19
AU2007253615A1 (en) 2007-11-29
US20140051698A1 (en) 2014-02-20
US20090131457A1 (en) 2009-05-21
CR10419A (es) 2011-07-19
ZA200809097B (en) 2009-11-25
CL2007001455A1 (es) 2008-05-16
AU2007253615B2 (en) 2011-06-23
US20180125849A1 (en) 2018-05-10
NO20084997L (no) 2008-12-22
EP2026811A1 (en) 2009-02-25
WO2007134828A1 (en) 2007-11-29
ECSP088902A (es) 2008-12-30
AR061057A1 (es) 2008-07-30
IL195017A0 (en) 2009-08-03
JP2009537580A (ja) 2009-10-29
TNSN08478A1 (en) 2010-04-14
TW200806665A (en) 2008-02-01
BRPI0712022A2 (pt) 2011-12-27
AR110051A2 (es) 2019-02-20
GB0610242D0 (en) 2006-07-05
RU2008150619A (ru) 2010-06-27

Similar Documents

Publication Publication Date Title
PE20080315A1 (es) DERIVADOS DE PIRAZOLO-[3,4-d]-PIRIMIDINAS COMO INHIBIDORES DE CINASA PI-3
PE20120107A1 (es) Inhibidores de proteina cinasa
PE20091687A1 (es) Derivados de piridina o pirazina como inhibidores de cinasa-pi-3
PE20121471A1 (es) Derivados de sulfonamida heterociclicos utiles como inhibidores de mek
PE20121506A1 (es) Compuestos triazolopiridinas como inhibidores de c-met
PE20090944A1 (es) PIRIMIDINAS BICICLICAS FUSIONADAS COMO INHIBIDORES DE LA VIA Pi3K/AKT
PE20151249A1 (es) Derivados de pirazolopirimidina como inhibidores de jak quinasas
PE20110545A1 (es) Compuestos de triazolopiridina como inhibidores de jak
PE20110944A1 (es) DERIVADOS DE PIRAZOLO[3,4-d]PIRIMIDINA COMO INHIBIDORES PDE1
PE20141655A1 (es) Compuestos de imidazopirrolidinona
PE20120493A1 (es) Pirimidinonas como inhibidores de pi3k
PE20081354A1 (es) Compuestos de azaindolilo como inhibidores de mek
PE20120494A1 (es) {5-[4-(3,3-DIMETIL-AZETIDINA-1-CARBONIL)-FENIL]-[1,2,4]TRIAZOLO[1,5-a]PIRIDIN-2-IL}-AMIDA DE ACIDO CICLOPROPANOCARBOXILICO COMO INHIBIDOR DE LAS QUINASAS JANUS
PE20070002A1 (es) Compuestos derivados de heteroaril como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa tipo i
PE20090370A1 (es) Derivados de heterociclo fusionado como inhibidores de quinasa
PE20090880A1 (es) Compuestos heterociclicos como inhibidores de fosfatidilinositol 3-cinasa
PE20090887A1 (es) DERIVADOS DE 1H-PIRAZOL-[3,4-d]-PIRIMIDINA, 9H-PURINA Y 7H-PIRROL-[2,3-d]-PIRIMIDINA COMO INHIBIDORES DE CINASA P70 S6
PE20060479A1 (es) Compuestos heteroaril-aril-ureas como inhibidores de la quinasa
PE20080059A1 (es) Quinazolinas para la inhibicion de pdk1
PE20091408A1 (es) Compuestos y composiciones como inhibidores de cinasa
PE20091068A1 (es) Compuestos pirrolo[3,2-d]pirimidina y su uso como inhibidores de quinasa pi3 y quinasa mtor
PE20120534A1 (es) PIRIMIDINAS FUSIONADAS COMO INHIBIDORES DE Akt
PE20131210A1 (es) Derivados de 5-anilinoimidazopiridina como inhibidores de mek
PE20110411A1 (es) Imidazopiridazinacarbonitrilos como inhibidores de quinasa
BR112012020557A2 (pt) formas cristalinas de sódio 4- {[9-cloro-7-(2-flúor-6-metoifenil)-5h-pirimido [5,4-d] [2] benzazepin-2-il]-amino}-2 metoxibenzoato de sódio.

Legal Events

Date Code Title Description
FC Refusal